These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 28636828)
1. Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity. Hurren KM; Dunham MW Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):891-896. PubMed ID: 28636828 [TBL] [Abstract][Full Text] [Related]
2. Evaluation of lorcaserin for the treatment of obesity. Berlie HD; Hurren KM Expert Opin Drug Metab Toxicol; 2013 Aug; 9(8):1053-9. PubMed ID: 23802690 [TBL] [Abstract][Full Text] [Related]
3. Safety and tolerability review of lorcaserin in clinical trials. Greenway FL; Shanahan W; Fain R; Ma T; Rubino D Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785 [TBL] [Abstract][Full Text] [Related]
4. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
6. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
7. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Singh AK; Singh R Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555 [No Abstract] [Full Text] [Related]
9. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Nguyen CT; Zhou S; Shanahan W; Fain R Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567 [TBL] [Abstract][Full Text] [Related]
10. New obesity agents: lorcaserin and phentermine/topiramate. Fleming JW; McClendon KS; Riche DM Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750 [TBL] [Abstract][Full Text] [Related]
11. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Higgins GA; Fletcher PJ; Shanahan WR Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010 [TBL] [Abstract][Full Text] [Related]
12. Lorcaserin Hcl for the treatment of obesity. Shukla AP; Kumar RB; Aronne LJ Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579 [TBL] [Abstract][Full Text] [Related]
13. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689 [TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931 [TBL] [Abstract][Full Text] [Related]
15. Single- and Multiple-dose Pharmacokinetics of a Lorcaserin Extended-release Tablet. Christopher R; Morgan M; Ferry J; Rege B; Tang Y; Kristensen A; Shanahan W Clin Ther; 2016 Oct; 38(10):2227-2238.e4. PubMed ID: 27692638 [TBL] [Abstract][Full Text] [Related]
16. Lorcaserin: a review of its use in chronic weight management. Hoy SM Drugs; 2013 Apr; 73(5):463-73. PubMed ID: 23529825 [TBL] [Abstract][Full Text] [Related]